

IN THE SPECIFICATION

Under 37 C.F.R. § 1.121(b), please amend the specification as indicated below:

Please replace the paragraph beginning on page 19, line 12, and ending on page 20, line 2, with the following replacement paragraph:

---The cytotoxic properties of a compound of the invention can also be determined using *in vivo* pharmacological models which are well known to the art. For example, compound **16a** was tested in a xenograft model. This assay consisted of injecting nude mice subcutaneously with human tumor cells. The tumors were allowed to grow until a measurable mass was present (22 days), and a single dose of **16a** was administered subcutaneously. The tumor size was measured periodically and the growth inhibition of the tumor was determined. The A498₂LM cell line, a sub-line of the A498 human kidney carcinoma, was used for the xenograft assay. The A498₂LM sub-line, which has a high DT-diaphorase level (1010 nmol cytochrome c reduced/min/mg protein), was developed by implanting the A498 cell line in mice and collecting the lung metastases that formed from the original tumor. Compound **16a** exhibited a 40% growth inhibition on Day 38 after a single dose of 25 mg/kg (~~Graph 2~~FIG. 2). ---

Please delete the illustration on page 20, at line 3, entitled “Graph 2: Tumor Response to 16A.”

Under 37 C.F.R. § 1.74, please amend the specification as indicated below:

Please add the following description to the Brief Description of the Figures on page 4, at line 3:

--- FIG. 2 illustrates the response of the A498 human kidney carcinoma tumor to compound **16A**. ---